Overview

AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with haematopoietic progenitors transplant.

Phase:

Phase 4

Details

Lead Sponsor:

PETHEMA Foundation

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Aprepitant
Fosaprepitant
Granisetron
Palonosetron